The number of failures in the Alzheimer's drug research field has been piling up disproportionately compared to successes in recent years, and the New York Academy of Sciences is hoping to change that by proposing a more streamlined, efficient path for Alzheimer's drug development.
Narges Bani Asadi, founder and CEO of Bina Technologies By Narges Bani Asadi One of the elements lacking in the personalized medicine discussion today is the perspective of clinicians and...
Scientists have found a new biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF, a discovery that could help better tailor treatment therapies for patients with these cancers.
Quintiles, the world's largest CRO, has launched a study to determine whether preprofiling cancer patients for key biomarkers can ease trial enrollment and speed drug development.
Quintiles has kicked off a study to determine whether early genomic profiling of cancer patients can help inform physician decisions and match the right participant with the right study, a method the CRO said could speed up the development process of personalized drugs.
Now that targeted therapies like Roche's Zelboraf and Bayer's Stivarga have raced through the FDA and into patients' hands, drug developers are relying less and less on old-fashioned randomized controlled trials.
As genetic sequencing technology advances and scientists begin to unravel the underlying genetic factors in various types of cancer, it is now increasingly possible to find out why promising drugs have little or no effect in some patients and identify in which populations they have the most potential.
Diagnostics outfit Foundation Medicine is hopping on the IPO bandwagon. It said it plans to raise $75 million by offering 5 million shares at a price range of $14 to $16.
As the genomics community inches closer to realizing the $1,000 genome, Genia Technologies has landed $5.3 million, the largest NIH grant to date under a program to advance genome sequencing technology.
In the last few decades, 3-D printing has become a reality--no longer the stuff of science fiction. It's mostly known for its capability to create prototypes, spare parts and other objects cheaply, quickly and accurately, but the technology is starting to find its place in biotech and medicine.